ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2022
Projecting the long-term societal value of a disease-modifying treatment for Alzheimer's disease in the United States.
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- The Multiple Criteria Qualitative Value-Based Pricing Framework "MARIE" for Novel Cell and Gene Therapy.Clinical pharmacology and therapeutics · 2026Article
- Estimated labor market outcomes of people progressing from preclinical to early-stage Alzheimer's disease in the United States.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Towards a Multi-sectoral Approach to Population Health: A Scoping Review of Cross-sectoral Evaluations of Health Interventions.Applied health economics and health policy · 2026Review
- Updated Conversion Table for the Multiple Criteria Qualitative Value-Based Pricing Framework "MARIE".Journal of market access & health policy · 2026Article
- Genetic risk in Alzheimer's disease.NPJ systems biology and applications · 2026Review
- Estimating the Future Health and Social Care Costs of Alzheimer's Disease Dementia in the UK: Impact of Disease Modifying Therapy Efficacy, Uptake, and Care Model - A Scenario Modelling Study.International journal of geriatric psychiatry · 2026Article
- Pharmacologic reversal of advanced Alzheimer's disease in mice and identification of potential therapeutic nodes in human brain.Cell reports. Medicine · 2026Article
- Hydrophobic Drug Delivery Platforms Based on Covalent Organic Frameworks for Combined Treatment of Alzheimer's Disease.International journal of molecular sciences · 2025Article
- A preliminary economic evaluation of a potential program for the primary prevention of Alzheimer's disease.The journal of prevention of Alzheimer's disease · 2025Article
- Global Societal Burden of Alzheimer's Disease by Severity: a Targeted Literature Review.Neurology and therapy · 2025Review
- Implications of treatment duration and frequency for value and cost-effective price of Alzheimer treatments.Journal of managed care & specialty pharmacy · 2024Article
- Scenarios for the long-term efficacy of amyloid-targeting therapies in the context of the natural history of Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- U.S. dementia care spending by state: 2010-2019.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- The Value of Medicare Coverage on Depressive Symptoms Among Older Immigrants.The Gerontologist · 2024Article
- Medical Costs and Caregiver Burden of Delivering Disease-Modifying Alzheimer's Treatments with Different Duration and Route of Administration.The journal of prevention of Alzheimer's disease · 2024Article
- Societal Costs of Dementia: 204 Countries, 2000-2019.Journal of Alzheimer's disease : JAD · 2024Article
- Using Alzheimer's disease blood tests to accelerate clinical trial enrollment.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2023Article
- Health Care Resource Use and Social Costs in Mild Cognitive Impairment and Mild Alzheimer's Disease.Journal of Alzheimer's disease reports · 2023Article
- The Case for a Novel Therapeutic Approach to Dementia: Small Molecule Hepatocyte Growth Factor (HGF/MET) Positive Modulators.Journal of Alzheimer's disease : JAD · 2023Review
- Projecting the long-term societal value of a disease-modifying treatment for Alzheimer's disease in the United States.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionWe estimate societal value of a disease-modifying Alzheimer's disease (AD) treatment that reduces progression by 30% in early stages.
methodsUsing the International Society for Pharmacoeconomics and Outcomes Research value flower as framework, we estimate gross societal value, that is, not including treatment cost, from avoided medical and social care costs, productivity and quality-adjusted life-years (QALY) gains for patients and caregivers, adjusting for severity of disease, value of financial insurance, and value of insurance for currently unafflicted adults with a Markov model.
resultsPredicted societal value from 2021 until 2041 is $2.62 trillion for the overall afflicted US population and $986 billion for the 2021 prevalent cohort or $134,418 per person, with valuation of patients' QALY gains (63%) and avoided nursing-home costs (20%) as largest components. Delays in access because of health system capacity constraints could reduce realized value between 52% and 69%. The value of insurance for the unafflicted is $4.52 trillion or $18,399 on average per person. DISCUSSION: With a total of $5.5 trillion, the projected gross societal value of a hypothetical AD treatment is substantial, which may help to put the cost of treatment into perspective.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.